Replimune Group, Inc. (REPL)
3.33
-0.11
(-3.20%)
USD |
NASDAQ |
May 07, 16:00
3.35
+0.02
(+0.60%)
After-Hours: 05:19
Replimune Group Research and Development Expense (Annual) : 191.22M for March 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| ANI Pharmaceuticals, Inc. | 51.66M |
| Bristol Myers Squibb Co. | 9.492B |
| Phathom Pharmaceuticals, Inc. | 32.78M |
| REGENXBIO, Inc. | 212.68M |
| Catalyst Pharmaceuticals, Inc. | 12.71M |